Dr. Fauci Says Gilead COVID-19 Drug Could Become ‘Standard Of Care’

(PresidentialWire.Com)- A medical breakthrough has been made in a drug that looks like it will be “the standard of care” for COVID-19.
Results from early clinical trials released Wednesday for remdesivir, an experimental antiviral drug created by Gilead Sciences Inc., were very positive. Data showed patients recovered more quickly from COVID-19 when they took the drug — 31% faster than those who took a placebo, in fact.
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, called the results “highly significant.”
“This is really quite important,” he said. “This will be the standard of care.
“The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery.”
Fauci compared these results to 1986 “when we were struggling for drugs for HIV and we had nothing.”
Fauci said he expects that the U.S. Food and Drug Administration will soon issue an emergency-use authorization for remdesivir so patients can start receiving it as treatment for COVID-19. Officials from the FDA have been in contact with officials from Gilead, but the agency hasn’t commented on granting regulatory approval for the drug just yet.
Fauci said he believes Gilead is committed to getting remdesivir available “as much as they can, as quickly as they can. I’m pretty confident that that will be the case because I believe they’re committed to trying to get this out as quickly as possible.”
The World Health Organization said it was too early for them to comment on the trial results, but President Donald Trump wants to continue pushing forward for FDA approval. He said:
“I want them to go as quickly as they can. We want everything to be safe, but we would like to see very quick approvals, especially with things that work.”
Gilead said it was preparing to donate the 1.5 million doses of remdesivir that it currently has, which would be enough to treat more than 140,000 patients. If it were given regulatory approval, then it would be available for commercial sale.
On Wednesday, Daniel O’Day, the CEO of Gilead, said:
“We are working to build a global consortium of pharmaceutical and chemical manufacturers to expand global capacity and production.”
O’Day also said the company is working on possibly bringing the treatment to a broader population of patients. To do so, they are working on different formulations of the drug itself as well as different means of delivery.
Remdesivir is a drug that’s administered as an intravenous infusion to patients who are hospitalized. Results from this latest clinical trial of the drug were eagerly anticipated by the medical community. It involved a large trial base of patients, and the patients who received the placebo and actual drug were randomized and unknown to the doctors administering it.
While Fauci’s reaction to the clinical trial results was very positive, some other medical professionals took a more muted stance. When the full dataset is released in mid-May, that will provide all the information most medical professionals need to see just how well remdesivir really performs.